Sung Young-sook, chairwoman of Hanmi Pharmaceutical Group, said in her New Year's message posted on the company intranet on ...
Shin Dong-guk invests 1.4 trillion won to resolve Hanmi Pharmaceutical dispute Shin Dong-guks hefty investment raises ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
THE CHOSUNILBO on MSN13d
“Alliance of Four” gains control amid Hanmi family’s year-long power struggleA year-long management dispute within the Hanmi Pharmaceutical Group family is nearing resolution. The conflict began in ...
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh Pharmaceutical Group Co. Ltd. for its investigational preclinical oral ...
Encequidar mesylate + paclitaxel is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 30 ...
In August 2020, Seoul, South Korea-based Hanmi Pharmaceutical Co. Ltd. exclusively licensed the once-weekly GLP-1/glucagon receptor dual agonist efinopegdutide for nonalcoholic steatohepatitis to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback